The chief scientific officer of CureDuchenne discussed challenges to tackle in the field.
Michael Kelly, PhD
Advertisement
Articles by Michael Kelly, PhD
The chief scientific officer of CureDuchenne discussed how nonviral approaches may address issues including gene size and redosability.
The chief scientific officer of CureDuchenne discussed research he is looking forward to seeing in 2024.
The chief scientific officer of CureDuchenne discussed progress in the field so far and upcoming milestones.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
Around the Helix: Cell and Gene Therapy Company Updates – October 22, 2025
2
AskBio’s Heart Failure Gene Therapy AB-1002 Shows Ability to Improve NYHA Class in Phase 1 Trial
3
CARsgen’s CAR-T Satri-Cel Significantly Reduces CA19-9 Levels in Patients With Pancreatic Ductal Adenocarcinoma
4
